Welcome to our dedicated page for Zynex SEC filings (Ticker: ZYXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to spot FDA risk disclosures or recurring supply revenue inside Zynex’s 200-page reports? Medical-device filings can bury the details that move the stock—whether it’s reimbursement trends, electrode reorder margins, or how new cardiac monitors could reshape growth.
Our platform solves this by linking each disclosure to the exact SEC form you need. The moment a Zynex quarterly earnings report 10-Q filing or Zynex 8-K material events explained hits EDGAR, AI generates a concise summary, flags segment revenue shifts, and highlights anything the market may miss. Real-time alerts surface Zynex Form 4 insider transactions real-time, so you never wait to learn when executives buy or sell.
Here’s what you can explore today:
- Annual perspective: A Zynex annual report 10-K simplified breakdown of FDA pathways, supply-chain dependencies, and reimbursement sensitivity.
- Quarter-to-quarter pulse: Instant AI commentary on margins, unit volume, and cash flow inside each 10-Q.
- Governance clarity: The Zynex proxy statement executive compensation decoded—see how pay aligns with R&D milestones.
- Insider visibility: Track every Zynex executive stock transactions Form 4 alongside trend analytics.
Need quick answers? Ask, “Zynex SEC filings explained simply,” “understanding Zynex SEC documents with AI,” or dive into our Zynex earnings report filing analysis to compare segment growth. Whether you’re researching Zynex insider trading Form 4 transactions or validating forecasts, Stock Titan delivers complete coverage—AI-powered summaries, expert annotations, and real-time updates across every filing type.
Zynex, Inc. (ZYXI) reported a new director appointment disclosure. A Form 3 initial statement of beneficial ownership was filed indicating the reporting person is a Director and no securities are beneficially owned. The event date is 10/07/2025, and the filing was made by a single reporting person. This is a routine governance filing that establishes the insider’s baseline holdings at zero.
Zynex, Inc. appointed Bret W. Wise to its Board, expanding the board from five to six members effective October 7, 2025. Wise will serve until the 2026 annual meeting and was named Chair of the Audit Committee, and a member of the Compensation and Nominating and Governance Committees.
Director compensation: Wise will receive annual cash retainers of $40,000 (Board), $20,000 (Audit Chair), $7,500 (Compensation Committee), and $5,000 (Nominating and Governance), paid quarterly in arrears and pro‑rated as applicable. He will also receive an initial grant of 20,000 restricted shares and an annual grant of 10,000 restricted shares upon re‑election, vesting quarterly over three years, beginning one quarter after grant, subject to continued service.
Additional updates: Chair Thomas Sandgaard will receive annual retainers of $150,000 (Board Chair) and $250,000 (Technology Committee Chair), paid quarterly in arrears. Chief Commercial Officer Anna Lucsok resigned effective October 10, 2025.
Vikram Singh Bajaj filed an SEC Form 3 reporting his initial statement of beneficial ownership for Zynex Inc (ZYXI). The reported event date is 08/18/2025. Mr. Bajaj is identified as an officer with the title Chief Financial Officer. The form states no securities are beneficially owned by the reporting person at the time of filing. The form was signed on 09/03/2025.
Steven Lewis Dyson is reported as both Chief Executive Officer and a director of Zynex Inc (ZYXI) on an initial Form 3. The filing discloses that no securities are beneficially owned by the reporting person and that the Form was filed by a single reporting person. The form shows no non‑derivative or derivative holdings and includes the reporting person’s address.
John T. Bibb, listed as both a Director and the company's Chief Legal Officer, filed an Initial Statement of Beneficial Ownership (Form 3) for Zynex Inc (ZYXI) reporting the event date 08/18/2025. The filing explicitly states that no securities are beneficially owned by the reporting person. The form is signed and dated 08/28/2025.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
